Type-2 Diabetic Neuropathy. Diabetic polyneuropathy
Conditions
Interventions
Intervention 1: The experimental groups participated 3 sessions per week for 12 weeks based on the training schedule with defined severity and duration (according to the standard protocol). Control g
Prevention
The experimental groups participated 3 sessions per week for 12 weeks based on the training schedule with defined severity and duration (according to the standard protocol). Control group received no
Sponsors
Vice chancellor for research, University of Tabriz
Vice chancellor for research, University of Mohaghegh Ardabili
Eligibility
Sex/Gender
Male
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age 30-70 Year; diabetic duration > 3 year; suffering from peripheral neuropathy; HbA1c = 6.5; FBS= 126 mg/dL; GTT = 200 mg/dL; lack of regular physical activity, Lack of medical Prohibition from physical activity Exclusion criteria: Cardiovascular disease; Cancer; Suspected Heart Disease; BMI > 40 kg/m2; Absence from the exercise
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HRV. Timepoint: Pre test; mid test 1; mid teat 2; post test. Method of measurement: Holter Monitoring VX3+.;Specification of Heart Structural and Functional. Timepoint: pre test; post test. Method of measurement: Echocardiography.;Hematology. Timepoint: pre test; post test. Method of measurement: Cell Counter.;Fbs, GTT. Timepoint: pre test; post test. Method of measurement: spectrophotometry.;Cholesterol; Triglycerides; HDL; LDL. Timepoint: pre test; post test. Method of measurement: spectrophotometry.;Insulin. Timepoint: pre test; post test. Method of measurement: Indirect immunofluorescense (IFA).;Body Composition. Timepoint: Pre test; mid test 1; mid teat 2; post test. Method of measurement: Body Composition Monitor.;Gas Analysis. Timepoint: pre test; post test. Method of measurement: Cortex Gas Analyser.;Anthropomorphic Indices. Timepoint: Pre test; mid test 1; mid test 2, post test. Method of measurement: Tape Measure.;Neuropathy. Timepoint: pre test; post test. Method of measurement: NCV test.;HbA1c. Timepoint: pre test, post test. Method of measurement: Bronate Affinity Assey. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life. Timepoint: Pre test; mid test 1; mid test 2; post test; detraining. Method of measurement: WHO quality of life-BREF 26 questionnaire; SF-36 questionnaire.;Insulin Resistance. Timepoint: pre test; post test. Method of measurement: HOMA-IR.;Depression. Timepoint: Pre test; mid test 1; mid teat 2; post test; detraining. Method of measurement: Beck's Depression Inventory.;Medicinal Plants. Timepoint: Pre test; mid test 1; mid teat 2; post test; detraining. Method of measurement: Interview and Questionnaire.;Family History of Diabetes. Timepoint: In the past and during the research. Method of measurement: Interview and Questionnaire.;Self Efficacy. Timepoint: Pre test; mid test 1; mid teat 2; post test; detraining. Method of measurement: Sherer Self Efficacy Scale.;Psychological Well-being. Timepoint: Pre test; mid test 1; mid test 2; post test; detraining. Method of measurement: Ryff’s Psychological Well-being Scales.;Sleep Quality and Quantity. Timepoint: Pre test; mid test 1; mid test 2; post test; detraining. Method of measurement: Sleep quality assessment(PSQI) and Sleep Duration.;Spiritual Health. Timepoint: Pre test; mid test 1; mid test 2; post test; detraining. Method of measurement: Ellison & Palutzian Spiritual Health. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElaheh Piralaiy
University of Mohaghegh Ardabili, University of Tabriz
Outcome results
None listed